Problems › AI Is Changing Our Industry › Healthcare Providers
The question is not what AI can do. It is which of your revenue lines gets cheaper for someone else to deliver. This page works through it for healthcare providers specifically — including an unedited excerpt from a real analysis of a healthcare provider.
The question is not what AI can do. It is which of your revenue lines gets cheaper for someone else to deliver. Healthcare providers carry a specific bind here — downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Until that is priced, cost per episode will keep moving for reasons nobody can attribute, and the debate about exposure by revenue line will stay a matter of opinion.
Most AI strategy conversations start from capability and end nowhere, because capability is not the variable that decides outcomes. The variable is whether the thing you charge for becomes dramatically cheaper for a competitor or a customer to produce themselves.
That is answerable line by line. For each revenue line: what fraction of the cost is the work being automated, how much of your price is defended by something other than that work, and how quickly could a credible competitor reach parity.
The uncomfortable finding is usually that the exposed lines are the profitable ones, because high-margin work is normally information work. The response is rarely to adopt faster; it is to move what you charge for toward whatever the automation makes more valuable rather than less.
These three together are the signature. One on its own usually points somewhere else.
✓ The pressure is showing up as price, not as lost deals
✓ Customers are asking why a task takes as long as it does
✓ A newer competitor prices a comparable output at a fraction of yours
The move that usually makes it worse. Adopting the tools without changing what you charge for, which lowers your cost and your price at the same time and leaves the margin where it was.
It is for you if you run or finance a healthcare provider and the pressure is showing up as price, not as lost deals. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Convert existing downside-risk scale into CMS-mandated quality infrastructure that locks in 48+ month structural durability.
The leak it closes. Binary default risk on $6.8M revenue eliminated through cost-per-episode analytics
The assumption it rests on. CMS continues ACO REACH program through 2030 — the engine put the probability at 0.85.
| Investment required | $225-325K total over 36 months ($75K regulatory consultant + $150-250K analytics tooling) |
| Expected return | 69.8× on $325K investment if ACO REACH approved — derived from $22.7M NPV upside / $325K investment |
| Revenue, year 1 | $0 incremental (application phase) |
| Revenue, year 2 | $1.0M incremental (0.5 point margin lift on $196M) |
| Revenue, year 3 | $2.0M incremental (1.0 point margin lift on $196M) |
| Exit criteria | Abandon if CMS terminates ACO REACH program OR physician ownership falls below 55% OR application rejected after two submissions |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to AI Horizon, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Internally first is usually right, because it produces evidence about your own economics before you make promises to customers. The exception is when a competitor has already reset the customer expectation, in which case internal efficiency arrives too late.
Judge by price, not by announcements. When the market price for the output you sell begins to fall, the disruption has arrived regardless of what the technology can demonstrate.
Smaller businesses usually have the advantage of being able to change what they charge for quickly. The move that matters is repositioning, and it is cheaper for you than for an incumbent with a large base to protect.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.